Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients-Reference-Cited by-同舟云学术

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

Published:2017-03-17 Issue:8 Volume:24 Page:2161-2167
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Clifton G. Travis,Litton Jennifer K.,Arrington Karen,Ponniah Sathibalan,Ibrahim Nuhad K.,Gall Victor,Alatrash Gheath,Peoples George E.,Mittendorf Elizabeth A.

Funder

Nancy Owens Memorial Foundation

Norwell Inc/Henry M. Jackson Foundation

National Cancer Institute

Society of Surgical Oncology/Susan G. Komen for the Cure

United States Military Cancer Institute

Jeanne F. Shelby Scholarship Fund

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-017-5844-0/fulltext.html

Reference29 articles.

1. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.

2. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62.

3. Beano A, Signorino E, Evangelista A, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:25.

4. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122(3):1066–1075.

5. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002;195(1):125–133.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of an obesity-related multi-gene prognostic model incorporating clinical characteristics in luminal breast cancer;iScience;2024-03

2. Advanced nano-based strategies for mRNA tumor vaccine;ACTA PHARM SIN B;2024

3. Advanced nano-based strategies for mRNA tumor vaccine;Acta Pharmaceutica Sinica B;2024-01

4. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors;The Journal of Immunology;2023-05-19

5. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment;Journal of Cancer Research and Clinical Oncology;2023-01-24